Valentina Gandin


Department of Pharmaceutical and Pharmacological Sciences, University of Padova
via F. Marzolo 5, 35131 Padova - Italy

Position: Associate Professor of Medicinal Chemistry (CHIM/08)

phone: +39-049-827-5351
fax:  +39-049-827-5366
skype: valentina.gandin 

  Short CV

Born in 1980

2005: Degree in Chemistry and Pharmaceutical Techniques, University of Padova

2006-2009: PhD in Molecular Sciences (Pharmaceutical Sciences), Dept. of Pharmaceutical Sciences, University of Padova

2007-2008: Visiting PhD student at the Dept. of Laboratory Medicine, Div. of Pathology, Karolinska Institutet, Stockholm

2009-2012: Post-Doc at the Dept. of Pharmaceutical and Pharmacological Sciences, University of Padova

2012-2017: Assistant Professor of Medicinal Chemistry (CHIM/08) 

2017-present: Associate Professor of Medicinal Chemistry (CHIM/08)



  Scientific Activities

The research activity principally focuses on the discovery and development of novel tumor-specific and target-specific antitumor agents endowed with improved pharmacological properties in comparison with reference chemotherapeutic drugs.

Besides primarily aimed at identifying structure-activity relationships (SARs) and selecting “Lead” compounds, these studies also provide mechanistic investigations for the recognition of biological and molecular determinants accounting for the antitumor activity of these new antitumor agents. 

Presently, the main research topics are:

  • Target-specific non platinum-based metallodrugs
  • Unconventional multi-targeted Pt(IV) complexes
  • PDK inhibitors
  • Organic and metallorganic selenium derivatives
  • Tellurium complexes

V. Gandin is a member of the Italian Chemical Society (Rome, Italy) and of the Interuniversity Society for Research on Metal Chemistry in Biological Systems (Bari, Italy).

  Technical expertise

In vitro and cell-free biochemical assays to validate protein target and off-target interactions

In vitro 2D and 3D cell culture assays to evaluate antitumor potential

Standard molecular biology and immunological assays for drug mechanistic investigations

In vivo antitumor tests on syngeneic and chimeric mice models 


  1. Raveendran R., Braude J.P., Wexselblatt E., Novohradsky V., Stuchlikova O., Brabec V., Gandin V. Gibson D. (2016) Pt(IV) derivatives of cisplatin and oxaliplatin with phenylbutyrate axial ligands are potent cytotoxic agents that act by several mechanisms of action. Chem. Sci., DOI: 10.1039/C5SC04205D.
  2. Martins I.L., Charneira C., Gandin V., Ferreira da Silva J.L., Justino G.C., Telo J.P., Vieira A.J., Marzano C., Antunes A.M. (2015) Selenium-Containing Chrysin and Quercetin Derivatives: Attractive Scaffolds for Cancer Therapy. J Med Chem., 58, 4250−4265.
  3. Gandin V., Tisato F., Dolmella A., Pellei M., Santini C., Giorgetti M., Marzano C., Porchia M. (2014) In Vitro and in Vivo Anticancer Activity of Copper(I) Complexes with Homoscorpionate Tridentate Tris(pyrazolyl)borate and Auxiliary Monodentate Phosphine Ligands. J Med Chem., 57, 4745-60.
  4. Gandin V., Fernandes A.P., Rigobello M.P., Dani B., Sorrentino F., Tisato F., Bjornstedt M., Bindoli A., Sturaro A., Rella R., Marzano C. (2010) Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductase. Biochem. Pharmacol., 79, 90–101.

Gandin V., Nyström C., Rundlöf A.K., Jönsson-Videsäter K., Schönlau F., Hörkkö J., Björnstedt M., Fernandes A.P. (2009) Effects of the antioxidant Pycnogenol on cellular redox systems in U1285 human lung carcinoma cells. FEBS J., 276, 532-540. 


  • Method of treating colorectal cancer. Patent US 9,220,705. Authors: James D. Hoeschele, Nicola Margiotta, Valentina Gandin, Emanuele Petruzzella, Cristina Marzano. 
  •  [Cu(thp)4]n[X]-n Compounds for the Treatment of a Broad Range of Human Solid Tumors, Including Refractory Tumors. Patent US 9,114,149 Authors: Cristina Marzano, Marina Porchia, Francesco Tisato, Carlo Santini, Maura Pellei, Giancarlo Gioia Lobbia, Grazie Papini.

  Research projects and Funds

  • Progetto di PRID2016 “New selective Class III Receptor Tyrosine Kinase inhibitors for cancer treatment” (C92F16002500005), Participant.
  • PRAT 2013 - University of Padova, “Novel organoselenium derivatives as multitarget anticancer drugs” (CPDA131114/13), Principal Investigator. 
  • PROGETTO GIOVANI 2011- University of Padova, "Bioinorganic target-specific anticancer drugs: structure-activity relationships and biological investigation on their mechanism of action" (GRIC117ET0), Principal Investigator. 
  • PRAT 2011 - University of Padova, "Transition metal carbene functionalized magnetic nanoparticles: design, synthesis, characterization and application in magnetic fluid hyperthermia" (CPDA114144), Participant.   
  • Bilateral Project for Scientific and Technological Cooperation CNR (Italy) and MTA (Hungary) 2010-2012 "Metals in neurodegenerative diseases: a model study for a metal-targeted therapy" Participant. 
  •  PRIN 2007, MIUR, "Progettazione e sintesi di complessi di rame per lo sviluppo di farmaci bioinorganici target-specifici" (20078EWK9B), Participant.